InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,217.67
(
0.07%
)
US TECH 100
17,676.00
(
0.20%
)
Dow Jones
39,477.37
(
0.23%
)
Brent Oil
83.66
(
-0.35%
)
Bitcoin
61,041.15
(
-3.14%
)
Post# of 251781
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Whalatane

Send PM Follow Ignore
Followers 119
Posts 20269
Boards Moderated 0
Alias Born 06/13/2011

Whalatane

Member Level

Re: None

Thursday, 02/22/2018 12:16:47 PM

Thursday, February 22, 2018 12:16:47 PM

Post# of 251781
OMER down another 16% on updated short report

https://www.prnewswire.com/news-releases/fourworld-capital-spotlights-90-sales-collapse-of-omeros-sole-product-omidria-in-past-two-months-reflecting-companys-weakening-state-300602007.html

OMS721 for IgA Nephropathy looked very promising to the Nephrologists my wife works with ......but evaporating sales of OMER's one drug and difficulty enrolling / cost of a large pivotal P3 trial seems to be tanking this Co.
Any comments ?
I held small position as a reminder that no matter how good the story sounds ...buyer beware
Kiwi
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up